{
    "clinical_study": {
        "@rank": "112648", 
        "arm_group": {
            "arm_group_label": "Nalmefene 18 mg", 
            "arm_group_type": "Experimental", 
            "description": "18 mg nalmefene corresponds to 20 mg nalmefene hydrochloride"
        }, 
        "brief_summary": {
            "textblock": "To investigate if renal impairment will have an impact on the pharmacokinetics of nalmefene"
        }, 
        "brief_title": "Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects", 
        "condition": "Renal Impairment", 
        "condition_browse": {
            "mesh_term": "Renal Insufficiency"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy young subjects and subjects with renal impairment with a Glomerular\n             Filtration Rate (GFR) of 50-80 ml/min/1.73m2, 30-<50 ml/min/1.73m2, <30 ml/min/1.73m2\n             will be included in the study.\n\n          -  The subjects must have a BMI between 19 and 32 kg/m2.\n\n        Exclusion Criteria:\n\n          -  The subject has a history of renal transplant or is undergoing dialyse treatment.\n\n          -  The subject is, in the opinion of the investigator, unlikely to comply with the\n             protocol or is unsuitable for any reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "32", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934166", 
            "org_study_id": "15084A", 
            "secondary_id": "2012-005711-53"
        }, 
        "intervention": {
            "arm_group_label": "Nalmefene 18 mg", 
            "description": "One single oral dose of 18 mg", 
            "intervention_name": "Nalmefene 18 mg", 
            "intervention_type": "Drug", 
            "other_name": "Selincro\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Nalmefene"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 9, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Munich", 
                    "country": "Germany", 
                    "zip": "81241"
                }, 
                "name": "DE801"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Interventional, Single-site, Open-label, Four-group, Single-dose Study Investigating the Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment (Mild, Moderate, or Severe) and in Healthy Subjects", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "For nalmefene and the metabolite nalmefene 3-O-glucuronide: area under the plasma concentration-time curve from zero to infinity (AUC0-inf)", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }, 
            {
                "measure": "For nalmefene and the metabolite nalmefene 3-O-glucuronide: area under the plasma concentration-time curve from zero to time t (t being the time for last quantifiable concentration) (AUC0-t)", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }, 
            {
                "measure": "For nalmefene and the metabolite nalmefene 3-O-glucuronide: maximum observed concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }, 
            {
                "measure": "For nalmefene and the metabolite nalmefene 3-O-glucuronide: nominal time corresponding to the occurrence of Cmax (tmax)", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }, 
            {
                "measure": "For nalmefene and the metabolite nalmefene 3-O-glucuronide: apparent elimination half life in plasma (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }, 
            {
                "measure": "For nalmefene and the metabolite nalmefene 3-O-glucuronide: renal Clearance (CLR)", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }, 
            {
                "measure": "For nalmefene: oral clearance for nalmefene defined as dose/AUC0-inf (CL/F)", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }, 
            {
                "measure": "For nalmefene: apparent volume of distribution for nalmefene (Vz /F)", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }, 
            {
                "measure": "For the metabolite nalmefene 3-O-glucuronide: metabolic ratio (MR) defined as AUC0-inf,metabolite/AUC0-inf,parent", 
                "safety_issue": "No", 
                "time_frame": "Up to 120 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934166"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of adverse events", 
            "measure": "Safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 10 days"
        }, 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}